Pull to refresh
Logo
What Changed
Following Why Sign Up
AstraZeneca invests $2 billion in Summit Therapeutics for ADC combination strategy

AstraZeneca invests $2 billion in Summit Therapeutics for ADC combination strategy

Money Moves

AstraZeneca closes $2 billion Summit investment, adds breast cancer combination with Daiichi Sankyo

October 5th, 2026: AstraZeneca completes $2 billion Summit investment

Overview

Updated Oct 21

AstraZeneca closed its $2 billion Summit Therapeutics investment on October 5: a straight equity purchase with no royalties or milestones attached, according to Biotech Morning. The cash funds trials pairing Summit's ivonescimab, a bispecific antibody that blocks PD-1 and VEGF, with AstraZeneca's antibody-drug conjugates.

AstraZeneca, Daiichi Sankyo and Summit plan a Phase III trial of Datroway plus ivonescimab in first-line triple-negative breast cancer, and AstraZeneca will test its experimental gastric-cancer ADC Sone-Ve with ivonescimab. The FDA is due to decide by November 14 whether to approve ivonescimab for EGFR-mutated lung cancer.

Why it matters

If these combinations work, they could set a new standard for first-line lung, breast, and gastrointestinal cancer treatment.

Questions about this story

Free account needed to ask — your question is kept and asked for you right after sign-up. Answers are public.

No questions yet — be the first to ask.

Key Indicators

$2.5B
Summit's estimated cash after investment
BioSpace reports the deal brings Summit's cash to about $2.5 billion, funding ongoing Phase 3 readouts and extending the company's runway beyond a year.
$18.36
Conversion price AstraZeneca paid per share
The $2 billion investment converts to Summit common stock at $18.36 per share, a premium over the close on the day the deal was announced.

Voices

Curated perspectives — historical figures and your fellow readers.

Sign up to generate historical perspectives on this story.

Log in Sign Up

People Involved

SG
Susan Galbraith
Executive Vice President, Oncology Haematology R&D, AstraZeneca
Leading AstraZeneca's ADC combination strategy
 Pascal Soriot
Pascal Soriot
Chief Executive Officer, AstraZeneca
Driving AstraZeneca's oncology and ADC combination strategy

Organizations Involved

AstraZeneca
AstraZeneca
Pharmaceutical company
Investor and clinical collaborator

British-Swedish pharmaceutical giant with one of the industry's largest oncology portfolios.
Summit Therapeutics
Summit Therapeutics
Biopharmaceutical company (NASDAQ-listed)
Recipient of investment; licenses ivonescimab outside China

Nasdaq-listed biopharma holding rights to ivonescimab in major territories outside China.
Akeso Inc.
Akeso Inc.
Biopharmaceutical company (Hong Kong-listed)
Engineered ivonescimab; retains rights in China

Biotech that engineered ivonescimab and holds rights to it in China and other regions.
Daiichi Sankyo
Daiichi Sankyo
Pharmaceutical company
Clinical collaborator with AstraZeneca and Summit on Datroway combinations

Japanese drugmaker co-developing Datroway and Enhertu with AstraZeneca.

Timeline

March 2023 October 2026

7 events Latest: October 5th, 2026 · 1 month ago
Tap a bar to jump to that date

  1. AstraZeneca completes $2 billion Summit investment

    Latest Deal

    AstraZeneca closed its $2 billion equity purchase, buying about 109,000 preferred shares convertible into common stock at a 1:1,000 ratio, or $18.36 per common share.

  2. Soriot says Summit drug can anchor future cancer combinations

    Statement

    AstraZeneca CEO Pascal Soriot told CNBC that ivonescimab could drive future cancer combination treatments, days after the investment closed.

  3. AstraZeneca, Daiichi Sankyo team with Summit on Datroway combinations

    Deal

    The three companies agreed to test Datroway in combination with ivonescimab across tumor types including lung and breast cancer, starting with a Phase III trial in first-line triple-negative breast cancer.

  4. AstraZeneca invests $2 billion in Summit Therapeutics

    Deal

    AstraZeneca buys a ~12% stake and launches a clinical collaboration to test Sone-Ve with ivonescimab in gastrointestinal cancers.

  5. Sone-Ve shows survival benefit in gastric cancer trial

    Clinical

    AstraZeneca reports positive results from CLARITY-Gastric01, a Phase III trial in advanced gastric cancer; data set for ESMO Congress 2026.

  6. Ivonescimab approved in China

    Regulatory

    The PD-1/VEGF bispecific receives its first marketing authorization, for non-small cell lung cancer.

  7. AstraZeneca licenses Sone-Ve from KYM Biosciences

    Deal

    AstraZeneca gains a global exclusive license to Sone-Ve, a CLDN18.2-targeting antibody-drug conjugate.

Scenarios

1

FDA approves ivonescimab for EGFR-mutated NSCLC

Possible Resolves by Q2 2027

Discussed by: The companies and FDA review timeline; the drug's existing China approval gives it a development head start

The FDA is reviewing the Biologics License Application for ivonescimab in EGFR-mutated non-small cell lung cancer. Approval would give Summit its first marketed product outside China and validate the PD-1/VEGF mechanism ahead of the combination studies. The review is the nearest catalyst for the AstraZeneca stake.

2

Combination trials show promise; AstraZeneca deepens the alliance

Possible Resolves by End of 2028

Discussed by: Both companies, which stated intent to start gastrointestinal trials imminently and signed a non-binding MOU for a broader collaboration

The clinical collaboration in gastrointestinal cancers and the MOU to test ivonescimab with additional AstraZeneca medicines could expand into a wider alliance. If early data from Sone-Ve plus ivonescimab show a clear signal, AstraZeneca may increase its stake or formalize the MOU into a definitive agreement.

3

Combination trials falter; partnership stalls

Unlikely Resolves by End of 2028

Discussed by: Risks typical of early combination studies in oncology

The combination trials could fail to meet endpoints or show unexpected toxicity, slowing momentum. AstraZeneca's 12% stake would lose value, and the non-binding MOU might never become a definitive agreement. A single-asset biotech with no approved products outside China would face a harder funding market.

4

Phase III Datroway-ivonescimab trial launches in breast cancer

Likely Resolves by End of 2026

Discussed by: AstraZeneca, Daiichi Sankyo and Summit, which announced the plan on October 2

The three companies said they intend to begin a Phase III trial of Datroway plus ivonescimab in first-line triple-negative breast cancer. That would extend the PD-1/VEGF plus ADC strategy beyond the gastrointestinal work with Sone-Ve. Each company shares trial costs and keeps rights to its own medicine.

Historical Context

2 moments from history that rhyme with this story — and how they unfolded.

March 2019

AstraZeneca-Daiichi Sankyo Enhertu collaboration (2019)

AstraZeneca paid $1.35 billion upfront in a collaboration worth up to $6.9 billion with milestone payments, then the industry's largest antibody-drug conjugate deal, to co-develop and co-commercialize trastuzumab deruxtecan (Enhertu), a HER2-targeting ADC. AstraZeneca gained commercial rights outside Japan.

Then

Enhertu won approvals in breast, lung, and gastric cancers and became a blockbuster, cementing AstraZeneca's ADC strategy.

Now

The deal validated ADCs as a core oncology pillar and showed AstraZeneca's willingness to make large bets on licensed assets.

Why this matters now

The Summit investment repeats the Enhertu playbook — a big upfront payment to secure a drug that becomes the backbone of a franchise — now extending it to pair ADCs with a bispecific immunotherapy.

September 2020

Gilead acquires Immunomedics (2020)

Gilead paid $21 billion to acquire Immunomedics for Trodelvy (sacituzumab govitecan), an ADC approved for triple-negative breast cancer. The price reflected a bet that Trodelvy would become a major oncology franchise.

Then

Trodelvy won FDA approval and expanded into several cancer types, underpinning Gilead's oncology push.

Now

The deal demonstrated both upside and risk in single-asset ADC bets: the drug delivered, but growth later faced competition.

Why this matters now

Shows the scale of single-asset bets in oncology and the risk-reward of paying a premium for a pipeline-defining drug — the same gamble AstraZeneca is taking on ivonescimab.

Sources

(28)
+22
AstraZeneca (Cision) Reuters via KELO-FM AM-News / Business Wire Dealroom Investing News Network Mugglehead Investing.com Proactive Investors The National Tribune Wall Street Journal via Internationly U.S. SEC Summit Therapeutics (Business Wire) BioSpace Fierce Biotech The Pharma Vanguard European Pharmaceutical Review London Stock Exchange (RNS) PublicNow (Form 6-K) BioPharma Dive Nasdaq CNBC StockTitan Kalkine EuropaWire Biotech Morning AstraZeneca (Cision) AstraZeneca (Cision) London Stock Exchange (RNS)